Status:
COMPLETED
Impact on Risk Stratification of Overlap Syndrome Phenotype in Patients With E1784K Mutation in SCN5A
Lead Sponsor:
Centre Hospitalier Universitaire de la Réunion
Conditions:
Long QT Syndrome
Brugada Syndrome
Eligibility:
All Genders
12+ years
Brief Summary
In patients expressing the SCN5A-E1784K mutation (Glu1784Lys), cardiovascular risk is difficult to define as the stratification of these patients is challenging. From our experience, major cardiovascu...
Detailed Description
Study design: This study will compare the occurrence of MCE between patients with overlap syndrome phenotype and patients with a single phenotype (whether Brugada syndrome or Long QT syndrome type 3) ...
Eligibility Criteria
Inclusion
- genotype E1784K (glu1784lys) in SCN5A gene
Exclusion
- none
Key Trial Info
Start Date :
April 5 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 20 2024
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT05274646
Start Date
April 5 2022
End Date
March 20 2024
Last Update
August 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de La Réunion
Saint-Pierre, France, Reunion, 97440